{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T14:00:55Z","timestamp":1793628055529,"version":"4.5.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007365","name":"Fondazione IRCCS Policlinico San Matteo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005699","name":"Universit\u00e0 degli Studi del Piemonte Orientale","doi-asserted-by":"publisher","award":["FAR_2016"],"award-info":[{"award-number":["FAR_2016"]}],"id":[{"id":"10.13039\/501100005699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005699","name":"Universit\u00e0 degli Studi del Piemonte Orientale","doi-asserted-by":"publisher","award":["FAR_2019"],"award-info":[{"award-number":["FAR_2019"]}],"id":[{"id":"10.13039\/501100005699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) is the most aggressive primary brain tumour for which both effective treatments and efficient tools for an early-stage diagnosis are lacking. Herein, we present curcumin-based fluorescent probes that are able to bind to aldehyde dehydrogenase 1A3 (ALDH1A3), an enzyme overexpressed in glioma stem cells (GSCs) and associated with stemness and invasiveness of GBM. Two compounds are selective versus ALDH1A3, without showing any appreciable interaction with other ALDH1A isoenzymes. Indeed, their fluorescent signal is detectable only in our positive controls in vitro and absent in cells that lack ALDH1A3. Remarkably, in vivo, our Probe selectively accumulate in glioblastoma cells, allowing the identification of the growing tumour mass. The significant specificity of our compounds is the necessary premise for their further development into glioblastoma cells detecting probes to be possibly used during neurosurgical operations.<\/jats:p>","DOI":"10.1038\/s42003-022-03834-7","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T14:03:16Z","timestamp":1662040996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Curcumin-based-fluorescent probes targeting ALDH1A3 as a promising tool for glioblastoma precision surgery and early diagnosis"],"prefix":"10.1038","volume":"5","author":[{"given":"Edoardo L. M.","family":"Gelardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Caprioglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Del Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0711-8269","authenticated-orcid":false,"given":"Daniele","family":"Mazzoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Mattoteia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Salamone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5112-9910","authenticated-orcid":false,"given":"Davide M.","family":"Ferraris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Aronica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Nato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7637-0006","authenticated-orcid":false,"given":"Annalisa","family":"Buffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7930-399X","authenticated-orcid":false,"given":"Menico","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-2720","authenticated-orcid":false,"given":"Lorenzo","family":"Magrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3640-2912","authenticated-orcid":false,"given":"Alberto","family":"Minassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-1729","authenticated-orcid":false,"given":"Silvia","family":"Garavaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"3834_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncology. 23, 1231\u20131251 (2021).","journal-title":"Neuro-Oncology."},{"key":"3834_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccr.2006.02.019","volume":"9","author":"HS Phillips","year":"2006","unstructured":"Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157\u2013173 (2006).","journal-title":"Cancer Cell"},{"key":"3834_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RGW Verhaak","year":"2010","unstructured":"Verhaak, R. G. W. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98\u2013110 (2010).","journal-title":"Cancer Cell"},{"key":"3834_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1101\/gad.187922.112","volume":"26","author":"GP Dunn","year":"2012","unstructured":"Dunn, G. P. et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26, 756\u2013784 (2012).","journal-title":"Genes Dev."},{"key":"3834_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23, 1124\u20131134 (2017).","journal-title":"Nat. Med."},{"key":"3834_CR6","doi-asserted-by":"publisher","first-page":"17301","DOI":"10.18632\/oncotarget.14230","volume":"8","author":"X Chen","year":"2017","unstructured":"Chen, X., Liao, R., Li, D. & Sun, J. Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications. Oncotarget 8, 17301\u201317312 (2017).","journal-title":"Oncotarget"},{"key":"3834_CR7","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.3390\/ijms20112746","volume":"20","author":"M Fedele","year":"2019","unstructured":"Fedele, M., Cerchia, L., Pegoraro, S., Sgarra, R. & Manfioletti, G. Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma. IJMS 20, 2746 (2019).","journal-title":"IJMS"},{"key":"3834_CR8","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/brain\/awz044","volume":"142","author":"J Behnan","year":"2019","unstructured":"Behnan, J., Finocchiaro, G. & Hanna, G. The landscape of the mesenchymal signature in brain tumours. Brain 142, 847\u2013866 (2019).","journal-title":"Brain"},{"key":"3834_CR9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","volume":"432","author":"SK Singh","year":"2004","unstructured":"Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396\u2013401 (2004).","journal-title":"Nature"},{"key":"3834_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature08712","volume":"463","author":"MS Carro","year":"2010","unstructured":"Carro, M. S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318\u2013325 (2010).","journal-title":"Nature"},{"key":"3834_CR11","doi-asserted-by":"publisher","first-page":"8644","DOI":"10.1073\/pnas.1221478110","volume":"110","author":"P Mao","year":"2013","unstructured":"Mao, P. et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc. Natl Acad. Sci. USA 110, 8644\u20138649 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3834_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"3834_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","volume":"376","author":"JR Perry","year":"2017","unstructured":"Perry, J. R. et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N. Engl. J. Med. 376, 1027\u20131037 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3834_CR14","doi-asserted-by":"publisher","first-page":"e0142856","DOI":"10.1371\/journal.pone.0142856","volume":"10","author":"W Zhang","year":"2015","unstructured":"Zhang, W. et al. ALDH1A3: a marker of mesenchymal phenotype in gliomas associated with cell invasion. PLoS ONE 10, e0142856 (2015).","journal-title":"PLoS ONE"},{"key":"3834_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1042\/BST20191261","volume":"48","author":"DM Ferraris","year":"2020","unstructured":"Ferraris, D. M., Gelardi, E. L. M., Garavaglia, S., Miggiano, R. & Rizzi, M. Targeting NAD-dependent dehydrogenases in drug discovery against infectious diseases and cancer. Biochem. Soc. Trans. 48, 693\u2013707 (2020).","journal-title":"Biochem. Soc. Trans."},{"key":"3834_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1124\/pr.111.005538","volume":"64","author":"V Koppaka","year":"2012","unstructured":"Koppaka, V. et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharm. Rev. 64, 520\u2013539 (2012).","journal-title":"Pharm. Rev."},{"key":"3834_CR17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1517\/17425255.4.6.697","volume":"4","author":"SA Marchitti","year":"2008","unstructured":"Marchitti, S. A., Brocker, C., Stagos, D. & Vasiliou, V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin. Drug Metab. Toxicol. 4, 697\u2013720 (2008).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"3834_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep35710","volume":"6","author":"A Moretti","year":"2016","unstructured":"Moretti, A. et al. Crystal structure of human aldehyde dehydrogenase 1A3 complexed with NAD+ and retinoic acid. Sci. Rep. 6, 35710 (2016).","journal-title":"Sci. Rep."},{"key":"3834_CR19","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/ijc.30091","volume":"139","author":"J-J Duan","year":"2016","unstructured":"Duan, J.-J., Cai, J., Guo, Y.-F., Bian, X.-W. & Yu, S.-C. ALDH1A3, a metabolic target for cancer diagnosis and therapy. Int. J. Cancer 139, 965\u2013975 (2016).","journal-title":"Int. J. Cancer"},{"key":"3834_CR20","doi-asserted-by":"publisher","first-page":"11018","DOI":"10.18632\/oncotarget.6920","volume":"7","author":"H Tomita","year":"2016","unstructured":"Tomita, H., Tanaka, K., Tanaka, T. & Hara, A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget 7, 11018\u201311032 (2016).","journal-title":"Oncotarget"},{"key":"3834_CR21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3390\/cancers11040502","volume":"11","author":"N Nwani","year":"2019","unstructured":"Nwani, N. et al. A novel ALDH1A1 inhibitor targets cells with stem cell characteristics in ovarian cancer. Cancers 11, 502 (2019).","journal-title":"Cancers"},{"key":"3834_CR22","doi-asserted-by":"publisher","first-page":"15279","DOI":"10.1021\/acs.jmedchem.0c01336","volume":"63","author":"PS Kharkar","year":"2020","unstructured":"Kharkar, P. S. Cancer stem cell (CSC) inhibitors in oncology\u2014a promise for a better therapeutic outcome: state of the art and future perspectives. J. Med. Chem. 63, 15279\u201315307 (2020).","journal-title":"J. Med. Chem."},{"key":"3834_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/cancers13020356","volume":"13","author":"ELM Gelardi","year":"2021","unstructured":"Gelardi, E. L. M. et al. A selective competitive inhibitor of aldehyde dehydrogenase 1A3 hinders cancer cell growth, invasiveness and stemness in vitro. Cancers 13, 356 (2021).","journal-title":"Cancers"},{"key":"3834_CR24","doi-asserted-by":"publisher","first-page":"7219","DOI":"10.1158\/0008-5472.CAN-15-2860","volume":"76","author":"P Cheng","year":"2016","unstructured":"Cheng, P. et al. FOXD1-ALDH1A3 signaling is a determinant for the self-renewal and tumorigenicity of mesenchymal glioma stem cells. Cancer Res. 76, 7219\u20137230 (2016).","journal-title":"Cancer Res."},{"key":"3834_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-021-02949-7","volume":"4","author":"J Li","year":"2021","unstructured":"Li, J. et al. A specific inhibitor of ALDH1A3 regulates retinoic acid biosynthesis in glioma stem cells. Commun. Biol. 4, 1\u201316 (2021).","journal-title":"Commun. Biol."},{"key":"3834_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.21037\/atm.2016.11.82","volume":"4","author":"DW Clark","year":"2016","unstructured":"Clark, D. W. & Palle, K. Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. Ann. Transl. Med. 4, 518 (2016).","journal-title":"Ann. Transl. Med."},{"key":"3834_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.biopha.2013.04.005","volume":"67","author":"R Januchowski","year":"2013","unstructured":"Januchowski, R., Wojtowicz, K. & Zabel, M. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed. Pharmacother. 67, 669\u2013680 (2013).","journal-title":"Biomed. Pharmacother."},{"key":"3834_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714\u2013726 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"3834_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.biocel.2016.07.017","volume":"78","author":"R Januchowski","year":"2016","unstructured":"Januchowski, R. et al. Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines. Int. J. Biochem. Cell Biol. 78, 248\u2013259 (2016).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"3834_CR30","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1021\/acs.jmedchem.9b01910","volume":"63","author":"L Quattrini","year":"2020","unstructured":"Quattrini, L. et al. Imidazo[1,2-a]pyridine derivatives as aldehyde dehydrogenase inhibitors: novel chemotypes to target glioblastoma stem cells. J. Med. Chem. 63, 4603\u20134616 (2020).","journal-title":"J. Med. Chem."},{"key":"3834_CR31","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1021\/acsmedchemlett.9b00686","volume":"11","author":"L Quattrini","year":"2020","unstructured":"Quattrini, L. et al. Progress in the field of aldehyde dehydrogenase inhibitors: novel Imidazo[1,2-a]pyridines against the 1A family. ACS Med. Chem. Lett. 11, 963\u2013970 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"3834_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2174\/1381612825666190313123704","volume":"25","author":"SH Shahcheraghi","year":"2019","unstructured":"Shahcheraghi, S. H. et al. Therapeutic potential of curcumin in the treatment of glioblastoma multiforme. Curr. Pharm. Des. 25, 333\u2013342 (2019).","journal-title":"Curr. Pharm. Des."},{"key":"3834_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.brainres.2009.01.066","volume":"1266","author":"S Purkayastha","year":"2009","unstructured":"Purkayastha, S. et al. Curcumin blocks brain tumor formation. Brain Res. 1266, 130\u2013138 (2009).","journal-title":"Brain Res."},{"key":"3834_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3058-2","volume":"17","author":"ZC Gersey","year":"2017","unstructured":"Gersey, Z. C. et al. Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species. BMC Cancer 17, 99 (2017).","journal-title":"BMC Cancer"},{"key":"3834_CR35","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","volume":"60","author":"KM Nelson","year":"2017","unstructured":"Nelson, K. M. et al. The essential medicinal chemistry of curcumin: miniperspective. J. Med. Chem. 60, 1620\u20131637 (2017).","journal-title":"J. Med. Chem."},{"key":"3834_CR36","doi-asserted-by":"publisher","first-page":"11194","DOI":"10.1039\/C5OB01847A","volume":"13","author":"K-S Park","year":"2015","unstructured":"Park, K.-S. et al. A curcumin-based molecular probe for near-infrared fluorescence imaging of tau fibrils in Alzheimer\u2019s disease. Org. Biomol. Chem. 13, 11194\u201311199 (2015).","journal-title":"Org. Biomol. Chem."},{"key":"3834_CR37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3892\/ijo.2017.4037","volume":"51","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells. Int. J. Oncol. 51, 467\u2013477 (2017).","journal-title":"Int. J. Oncol."},{"key":"3834_CR38","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1002\/chem.201504903","volume":"22","author":"K Kamada","year":"2016","unstructured":"Kamada, K. et al. Boron difluoride curcuminoid fluorophores with enhanced two-photon excited fluorescence emission and versatile living-cell imaging properties. Chem. Eur. J. 22, 5219\u20135232 (2016).","journal-title":"Chem. Eur. J."},{"key":"3834_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.4103\/ajns.AJNS_18_19","volume":"14","author":"M Hishii","year":"2019","unstructured":"Hishii, M., Matsumoto, T. & Arai, H. Diagnosis and treatment of early-stage glioblastoma. Asian J. Neurosurg. 14, 589\u2013592 (2019).","journal-title":"Asian J. Neurosurg."},{"key":"3834_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bmc.2015.11.044","volume":"24","author":"D Caprioglio","year":"2016","unstructured":"Caprioglio, D. et al. Triazole-curcuminoids: a new class of derivatives for \u2018tuning\u2019 curcumin bioactivities? Bioorg. Medicinal Chem. 24, 140\u2013152 (2016).","journal-title":"Bioorg. Medicinal Chem."},{"key":"3834_CR41","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1021\/jm500308c","volume":"57","author":"A Koeberle","year":"2014","unstructured":"Koeberle, A. et al. SAR studies on curcumin\u2019s pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. J. Med. Chem. 57, 5638\u20135648 (2014).","journal-title":"J. Med. Chem."},{"key":"3834_CR42","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1016\/j.bmc.2013.05.053","volume":"21","author":"A Caldarelli","year":"2013","unstructured":"Caldarelli, A., Penucchini, E., Caprioglio, D., Genazzani, A. A. & Minassi, A. Synthesis and tubulin-binding properties of non-symmetrical click C5-curcuminoids. Bioorg. Med. Chem. 21, 5510\u20135517 (2013).","journal-title":"Bioorg. Med. Chem."},{"key":"3834_CR43","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1021\/np400148e","volume":"76","author":"A Minassi","year":"2013","unstructured":"Minassi, A., S\u00e1nchez-Duffhues, G., Collado, J. A., Mu\u00f1oz, E. & Appendino, G. Dissecting the pharmacophore of curcumin. Which structural element is critical for which action? J. Nat. Prod. 76, 1105\u20131112 (2013).","journal-title":"J. Nat. Prod."},{"key":"3834_CR44","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/recl.19640830407","volume":"83","author":"HJJ Pabon","year":"1964","unstructured":"Pabon, H. J. J. A synthesis of curcumin and related compounds. Recl. Trav. Chim. Pays-Bas 83, 379\u2013386 (1964).","journal-title":"Recl. Trav. Chim. Pays-Bas"},{"key":"3834_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2174\/092986707779313471","volume":"14","author":"L Cai","year":"2007","unstructured":"Cai, L., Innis, R. B. & Pike, V. W. Radioligand development for PET imaging of beta-amyloid (Abeta)\u2013current status. Curr. Med. Chem. 14, 19\u201352 (2007).","journal-title":"Curr. Med. Chem."},{"key":"3834_CR46","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1002\/asia.201100432","volume":"6","author":"SG Agalave","year":"2011","unstructured":"Agalave, S. G., Maujan, S. R. & Pore, V. S. Click chemistry: 1,2,3-triazoles as pharmacophores. Chem. Asian J. 6, 2696\u20132718 (2011).","journal-title":"Chem. Asian J."},{"key":"3834_CR47","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/mp700113r","volume":"4","author":"P Anand","year":"2007","unstructured":"Anand, P., Kunnumakkara, A. B., Newman, R. A. & Aggarwal, B. B. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4, 807\u2013818 (2007).","journal-title":"Mol. Pharm."},{"key":"3834_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-2812-2","volume":"5","author":"H Van Nong","year":"2016","unstructured":"Van Nong, H. et al. Fabrication and vibration characterization of curcumin extracted from turmeric (Curcuma longa) rhizomes of the northern Vietnam. SpringerPlus 5, 1147 (2016).","journal-title":"SpringerPlus"},{"key":"3834_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cbi.2014.12.008","volume":"234","author":"CA Morgan","year":"2015","unstructured":"Morgan, C. A., Parajuli, B., Buchman, C. D., Dria, K. & Hurley, T. D. N,N-diethylaminobenzaldehyde (DEAB) as a substrate and mechanism-based inhibitor for human ALDH isoenzymes. Chem. Biol. Interact. 234, 18\u201328 (2015).","journal-title":"Chem. Biol. Interact."},{"key":"3834_CR50","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11060-018-03087-7","volume":"141","author":"R D\u00edez Valle","year":"2019","unstructured":"D\u00edez Valle, R., Hadjipanayis, C. G. & Stummer, W. Established and emerging uses of 5-ALA in the brain: an overview. J. Neurooncol. 141, 487\u2013494 (2019).","journal-title":"J. Neurooncol."},{"key":"3834_CR51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3171\/2016.7.JNS16232","volume":"127","author":"JA Neira","year":"2017","unstructured":"Neira, J. A. et al. Aggressive resection at the infiltrative margins of glioblastoma facilitated by intraoperative fluorescein guidance. J. Neurosurg. 127, 111\u2013122 (2017).","journal-title":"J. Neurosurg."},{"key":"3834_CR52","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3171\/2018.10.JNS181174","volume":"132","author":"GA Katsevman","year":"2019","unstructured":"Katsevman, G. A., Turner, R. C., Urhie, O., Voelker, J. L. & Bhatia, S. Utility of sodium fluorescein for achieving resection targets in glioblastoma: increased gross- or near-total resections and prolonged survival. J. Neurosurg. 132, 914\u2013920 (2019).","journal-title":"J. Neurosurg."},{"key":"3834_CR53","unstructured":"SigmaPlot Extract Graphs and Data Analysis (StatSys v12.3)SigmaPlot (RRID:SCR_003210). URL: http:\/\/www.sigmaplot.com\/products\/sigmaplot\/."},{"key":"3834_CR54","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ebiom.2015.08.026","volume":"2","author":"Y Xie","year":"2015","unstructured":"Xie, Y. et al. The human glioblastoma cell culture resource: validated cell models representing all molecular subtypes. EBioMedicine 2, 1351\u20131363 (2015).","journal-title":"EBioMedicine"},{"key":"3834_CR55","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3390\/cells9051249","volume":"9","author":"A Azzalin","year":"2020","unstructured":"Azzalin, A. et al. A new pathway promotes adaptation of human glioblastoma cells to glucose starvation. Cells 9, 1249 (2020).","journal-title":"Cells"},{"key":"3834_CR56","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1349-7006.2006.00208.x","volume":"97","author":"T Szatmari","year":"2006","unstructured":"Szatmari, T. et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 97, 546\u2013553 (2006).","journal-title":"Cancer Sci."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03834-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03834-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03834-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T01:05:42Z","timestamp":1668733542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03834-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3834"],"URL":"https:\/\/doi.org\/10.1038\/s42003-022-03834-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-567295\/v1","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"27 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interest: the work reported in these papers led to a patent name: \u201cPROBE DIRECTED TO ENZYME ALDH1A3 AND USE THEREOF IN THE DIAGNOSIS OF GLIOBLASTOMA\u201d; number: PCT\/IB2022\/053216 (6 April 2022); geographical region: International Application (PCT); applicants: University of Piemonte Orientale 90%; University of Pavia 10%; inventors: S.G., A.M., M.R., E.L.M.G., D.C., G.C., L.M.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"895"}}